Literature DB >> 24279580

Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.

V Carreño1.   

Abstract

BACKGROUND: There are patients with chronic hepatitis C who are not eligible for the current interferon-based therapies or refuse to be treated due to secondary effects. AIM: To provide information on alternative treatments for the management of these patients.
METHODS: A PubMed search was performed to identify relevant literature. Search terms included hepatitis C virus, anti-inflammatory treatment, antioxidant, natural products and alternative treatment, alone or in combination. Additional publications were identified using the references cited by primary and review articles.
RESULTS: Several approaches, such as iron depletion (phlebotomy), treatment with ursodeoxycholic acid or glycyrrhizin, have anti-inflammatory and/or anti-fibrotic effects. Life interventions like weight loss, exercise and coffee consumption are associated with a biochemical improvement. Other alternatives (ribavirin monotherapy, amantadine, silibinin, vitamin supplementation, etc.) do not have any beneficial effect or need to be tested in larger clinical studies.
CONCLUSION: There are therapeutic strategies and lifestyle interventions that can be used to improve liver damage in patients with chronic hepatitis C who cannot receive or refuse interferon-based treatments.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24279580     DOI: 10.1111/apt.12562

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

1.  Occurrence and Recurrence of Hepatocellular Carcinoma Were Not Rare Events during Phlebotomy in Older Hepatitis C Virus-Infected Patients.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shin Yasui; Masato Nakamura; Tatsuo Miyamura; Shuang Wu; Xia Jiang; Makoto Arai; Fumio Imazeki; Osamu Yokosuka
Journal:  Case Rep Oncol       Date:  2014-05-08

2.  Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress.

Authors:  Yao Wang; Qian Chen; Chunxia Shi; Fangzhou Jiao; Zuojiong Gong
Journal:  Mol Med Rep       Date:  2019-09-10       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.